BioHarvest Sciences vs MindWalk
BHST and HYFT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BHST and HYFT compare
MindWalk grew revenue faster over the last twelve months (43.4% versus 37.0% for BioHarvest Sciences).
MindWalk scores higher on the StockData Score (7 against 5 for BioHarvest Sciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BHST | HYFT |
|---|---|---|
| Size and price | ||
| Share price | $1.50 | $0.990 |
| Change, 1 year | −80.9% | −44.7% |
| Change, 5 years | −86.1% | −82.1% |
| Beta (5Y) | 0.87 | 1.36 |
| StockData Score | ||
| Total score | 5 | 7 (better) |
| Valuation score | 0 | 0 |
| Growth score | 2 | 2 |
| Performance score | 1 (better) | 0 |
| Health score | 2 | 5 (better) |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | 37.0% | 43.4% (better) |
| Revenue growth, 5Y average | – | −2.8% |
| Profitability | ||
| Gross margin | 59.3% | 60.8% (better) |
| Operating margin | −16.2% | – |
| Net margin | −32.3% | – |
| FCF margin | −27.8% (better) | −76.9% |
| Return on equity | −83.2% | – |
| Return on invested capital | −163% | – |
| Financial health | ||
| Debt / equity | 0.01 | – |
| Current ratio | 3.97 (better) | 1.84 |
| Piotroski F-score | 5 | – |
| Ownership | ||
| Held by institutions | 7.4% | 9.3% |
| Held by insiders | 0.00% | 0.00% |
| Short interest, % of float | 0.33% | – |
Go deeper
- BHST stock overview
- BHST income statement
- BHST valuation and score
- HYFT stock overview
- HYFT income statement
- HYFT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.